429 related articles for article (PubMed ID: 33682320)
21. Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial.
Yang X; Chen H; Xu D; Chen X; Li Y; Tian J; Wang D; Pang J
BMC Cancer; 2022 Feb; 22(1):177. PubMed ID: 35172779
[TBL] [Abstract][Full Text] [Related]
22. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
23. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
24. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
25. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
26. [
Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
J Nucl Med; 2023 Nov; 64(11):1726-1729. PubMed ID: 37709534
[TBL] [Abstract][Full Text] [Related]
27. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; van Gemert WA; de Groot M; Westdorp H; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
Trials; 2021 Nov; 22(1):768. PubMed ID: 34736509
[TBL] [Abstract][Full Text] [Related]
28. A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
Byeon S; Kim H; Jeon HG; Seo SI; Jeon SS; Lee HM; Lee SI; Park SH
BMC Cancer; 2021 Nov; 21(1):1281. PubMed ID: 34839812
[TBL] [Abstract][Full Text] [Related]
29. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
30. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
31. The effect of androgen deprivation therapy on
Onal C; Guler OC; Torun N; Reyhan M; Yapar AF
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
[TBL] [Abstract][Full Text] [Related]
32. [
Dietlein F; Mueller P; Kobe C; Endepols H; Hohberg M; Zlatopolskiy BD; Krapf P; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
Mol Imaging Biol; 2021 Apr; 23(2):277-286. PubMed ID: 33006028
[TBL] [Abstract][Full Text] [Related]
33. Administering [
Eapen RS; Buteau JP; Jackson P; Mitchell C; Oon SF; Alghazo O; McIntosh L; Dhiantravan N; Scalzo MJ; O'Brien J; Sandhu S; Azad AA; Williams SG; Sharma G; Haskali MB; Bressel M; Chen K; Jenjitranant P; McVey A; Moon D; Lawrentschuk N; Neeson PJ; Murphy DG; Hofman MS
Eur Urol; 2024 Mar; 85(3):217-226. PubMed ID: 37891072
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II Trial of the Combination of
Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L
Eur Urol Oncol; 2021 Dec; 4(6):963-970. PubMed ID: 32758400
[TBL] [Abstract][Full Text] [Related]
36. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
37. Tolerability of concurrent external beam radiotherapy and [
van der Sar ECA; Braat AJAT; van der Voort-van Zyp JRN; van der Veen BS; van Leeuwen PJ; de Vries-Huizing DMV; Hendrikx JMA; Lam MGEH; Vogel WV
BMC Cancer; 2023 Mar; 23(1):268. PubMed ID: 36959540
[TBL] [Abstract][Full Text] [Related]
38. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
40. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
